CN-121987704-A - Traditional Chinese medicine composition for preventing or treating metabolic syndrome combined with ejection fraction retention type heart failure and application thereof

Abstract

The invention relates to the field of traditional Chinese medicines. More particularly, relates to a traditional Chinese medicine composition for preventing or treating metabolic syndrome combined with ejection fraction retention type heart failure and application thereof. The traditional Chinese medicine composition is prepared from the following raw materials of snakegourd fruit, stir-fried medicated leaven, immature bitter orange, pinellia tuber, coptis root, astragalus root, red paeony root and divaricate saposhnikovia root. The traditional Chinese medicine composition provided by the invention is based on the pathological basis of the metabolic syndrome and the heart failure disease position and the pathological characteristics of the heart failure with reserved jet fraction, and realizes the prevention or treatment of the heart failure with reserved jet fraction of the metabolic syndrome by integrally conditioning the spleen and stomach transportation and transformation, resolving phlegm and promoting qi movement and dredging blood collaterals, thereby providing a safe, effective and long-term application traditional Chinese medicine prevention and treatment scheme for patients with heart failure with reserved jet fraction of the metabolic syndrome.

Inventors

• Song Qingqiao
• CHEN CHUNMEI
• ZHANG SIQI
• LIU YUETONG
• ZHAO LU
• MAO XINXIN

Assignees

• 中国中医科学院广安门医院

Dates

Publication Date

20260508

Application Date

20260312

Claims (10)

1. 1. The traditional Chinese medicine composition for preventing or treating metabolic syndrome combined ejection fraction retention type heart failure is characterized by comprising the following raw medicinal materials: fructus Trichosanthis, massa Medicata Fermentata preparata, fructus Aurantii Immaturus, rhizoma Pinelliae, coptidis rhizoma, radix astragali, radix Paeoniae Rubra, and radix Saposhnikoviae.
2. 2. The traditional Chinese medicine composition according to claim 1, wherein the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 8-16 parts of snakegourd fruit, 15-30 parts of stir-fried medicated leaven, 6-14 parts of immature bitter orange, 5-12 parts of pinellia tuber, 3-8 parts of coptis chinensis, 15-30 parts of astragalus membranaceus, 10-20 parts of red paeony root and 6-14 parts of radix sileris.
3. 3. The traditional Chinese medicine composition according to claim 1, wherein the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 12 parts of snakegourd fruit, 20 parts of stir-fried medicated leaven, 10 parts of immature bitter orange, 9 parts of pinellia tuber, 6 parts of coptis chinensis, 20 parts of astragalus root, 15 parts of red paeony root and 10 parts of divaricate saposhnikovia root.
4. 4. The traditional Chinese medicine composition according to claim 1, wherein the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 10 parts of snakegourd fruit, 18 parts of stir-fried medicated leaven, 12 parts of immature bitter orange, 8 parts of pinellia tuber, 5 parts of coptis chinensis, 25 parts of astragalus root, 12 parts of red paeony root and 8 parts of divaricate saposhnikovia root.
5. 5. The traditional Chinese medicine composition according to claim 1, wherein the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 15 parts of snakegourd fruit, 25 parts of stir-fried medicated leaven, 8 parts of immature bitter orange, 10 parts of pinellia tuber, 7 parts of coptis chinensis, 30 parts of astragalus root, 18 parts of red paeony root and 12 parts of divaricate saposhnikovia root.
6. 6. A traditional Chinese medicine preparation for preventing or treating metabolic syndrome combined with ejection fraction retention type heart failure, characterized in that raw materials of the traditional Chinese medicine preparation comprise the traditional Chinese medicine composition according to any one of claims 1-5.
7. 7. The traditional Chinese medicine preparation according to claim 6, wherein the traditional Chinese medicine preparation is in the form of decoction, granules, oral liquid, capsules or tablets.
8. 8. The traditional Chinese medicine preparation according to claim 7, wherein the decoction is prepared according to the following steps: Weighing fructus Trichosanthis, massa Medicata Fermentata preparata, fructus Aurantii Immaturus, rhizoma Pinelliae, coptidis rhizoma, radix astragali, radix Paeoniae Rubra and radix Saposhnikoviae according to formula amount, and decocting with water to obtain decoction.
9. 9. The traditional Chinese medicine preparation according to claim 6, further comprising pharmaceutically acceptable auxiliary materials.
10. 10. Use of a traditional Chinese medicine composition according to any one of claims 1-5 or a traditional Chinese medicine preparation according to any one of claims 6-9 for the preparation of any one of the following medicaments; 1) A drug that improves an index related to metabolic abnormalities; 2) A medicament for improving diastolic function in patients with heart failure with preserved ejection fraction.

Description

Traditional Chinese medicine composition for preventing or treating metabolic syndrome combined with ejection fraction retention type heart failure and application thereof Technical Field The invention relates to the field of traditional Chinese medicines. More particularly, relates to a traditional Chinese medicine composition for preventing or treating metabolic syndrome combined with ejection fraction retention type heart failure and application thereof. Background Metabolic syndrome (Metabolic Syndrome, metS) is a group of metabolic abnormality syndromes characterized mainly by central obesity, dyslipidemia, metabolic disorder of blood glucose and elevated blood pressure, and is an important risk factor for the occurrence and development of cardiovascular diseases. With aging population and changing lifestyle, the prevalence of MetS rises year by year, becoming an important public health problem affecting the prognosis of cardiovascular disease. Heart Failure (HFpEF) is an important type of Heart Failure and is mainly characterized by a relative retention of left ventricular ejection fraction, but there are pathological changes such as myocardial diastolic dysfunction and decreased cardiac compliance. HFpEF patients often combine MetS-related factors such as obesity, hypertension, diabetes, dyslipidemia, and the like, which overlap highly in the clinical population. The existing research shows that MetS is not only an important risk factor of HFpEF, but also can promote the change of myocardial structure and function through long-term metabolic abnormal state, thereby accelerating the occurrence and progress of HFpEF. Compared with heart failure with reduced ejection fraction, the pathogenesis of HFpEF is more complex, the clinical phenotype heterogeneity is obvious, the treatment means is limited, and the prognosis of patients is less ideal. At present, western medicine mainly comprises life style intervention and targeted drug treatment aiming at abnormalities such as blood pressure, blood sugar, blood fat and the like, and simultaneously improves heart failure symptoms by combining diuresis, heart strengthening and the like. However, the above treatments focus on single risk factors or symptomatic control, and there is still a lack of overall intervention against MetS combined with HFpEF complex pathological states, which is still insufficient in controlling patient disease progression and long-term prognosis. The occurrence and development of MetS and HFpEF are considered to be closely related to spleen dysfunction transportation, turbid phlegm endogenous generation, qi movement disorder, blood collateral disharmony and other factors by traditional Chinese medicine. Based on the overall view and dialectical treatment theory of traditional Chinese medicine, the Chinese medicinal composition capable of considering the pathological basis of MetS and improving the heart function of HFpEF is explored, and the Chinese medicinal composition has great significance for enriching the prevention and treatment means of the diseases. Disclosure of Invention The first aim of the invention is to provide a traditional Chinese medicine composition for preventing or treating metabolic syndrome combined with ejection fraction retention type heart failure. A second object of the present invention is to provide a Chinese medicinal preparation comprising the above-mentioned Chinese medicinal composition. A third object of the present invention is to provide an application of the above-mentioned Chinese medicinal composition or Chinese medicinal preparation in preparing a medicament for preventing or treating metabolic syndrome complicated with ejection fraction retention type heart failure. In order to achieve the first object, the present invention adopts the following technical scheme: the invention discloses a traditional Chinese medicine composition for preventing or treating metabolic syndrome combined with ejection fraction retention type heart failure, which is prepared from the following raw materials: fructus Trichosanthis, massa Medicata Fermentata preparata, fructus Aurantii Immaturus, rhizoma Pinelliae, coptidis rhizoma, radix astragali, radix Paeoniae Rubra, and radix Saposhnikoviae. The traditional Chinese medicine composition provided by the invention is based on the pathological basis of heart failure with reserved ejection fraction, takes the disease position and the disease characteristics of metabolic syndrome into consideration, carries out systematic intervention on the complex pathogenesis of 'phlegm turbidity-qi movement-blood collaterals' interweaving under the background of heart failure with reserved ejection fraction, and realizes the prevention or treatment of heart failure with reserved metabolic syndrome and reserved ejection fraction by integrally conditioning the transportation and transformation of spleen and stomach, resolving phlegm turbidity and promoting the circulation of qi movement